Drug Development for Gene Therapy
Translational Biomarkers, Bioanalysis, and Companion Diagnostics
1. Auflage Januar 2024
496 Seiten, Hardcover
Fachbuch
Weitere Versionen
Drug Development for Gene Therapy
Industry-centric perspective on translational and bioanalytical challenges and best practices for gene therapies
Drug Development for Gene Therapy focuses on the translational and bioanalytical challenges and best practices for gene therapy modalities, presenting a significant body of data, including information related to safety and efficacy, necessary to advance through the development pipeline into clinical use. The text covers bioanalytical methods and platforms including patient screening assays, different PCR tests, enzyme activity assays, ELISpot, NGS, LC/MS, and immunoassays, with FDA and EMA guidelines on gene therapy safety and efficacy, along with companion diagnostics regulations from US and EU perspectives.
The chapters offer an in-depth discussion of the basics and best practices for translational biomarkers, bioanalysis, and developing companion diagnostics / lab tests for gene therapies in the pharma and biopharma industries. To aid in reader comprehension, the text includes clinical examples of relevant therapies in related chapters. Some of the core topics covered include study design, immunogenicity, various bioanalytical methods and their applications, and global regulatory issues.
Written by two highly qualified authors with significant experience in the field, Drug Development for Gene Therapy includes information on:
* Bioanalytical methods to detect pre-existing antibodies against adeno-associated viruses (AAV) capsids
* Detection of cellular immunity and humoral response to viral capsids and transgene proteins, and immunogenicity of gene therapy products
* Nonclinical and clinical study considerations and methods for biodistribution and shedding
* Quantification of transgene protein expression and biochemical function, and substrate and distal pharmacodynamic biomarker measurements for gene therapy
* Detection and quantification of rAAV integration and off-target editing
* Current regulatory landscape for gene therapy product development and the role of biomarkers and general regulatory considerations for gene therapy companion diagnostics
With comprehensive coverage of the subject, Drug Development for Gene Therapy is a must-have resource for researchers and developers in the areas of pharmaceuticals, biopharmaceuticals, and contract research organizations (CROs), along with professors, researchers, and advanced students in chemistry, biological, biomedical engineering, pharmaceuticals, and medical sciences.
Preface xxiii
Section I Introduction 1
1 Introduction to AAV-based in vivo Gene Therapy 3
Oscar Segurado
1.1 Introduction 3
1.2 Advantages and Disadvantages for AAV in vivo 13
1.3 Technology Platforms of AAV-based in vivo Gene Therapy 14
1.4 AAV Serotypes and Tissue Affinity 18
1.5 Precision Medicine: Screening and Monitoring Biomarkers, Companion Diagnostics 19
1.6 Predictions for Scientific and Medical Progress 22
1.7 Predictions for Market Adoption 24
1.8 Final Thoughts 26
2 Recent Development in in vivo Clinical Gene Therapy Platforms 35
John Murphy and Jane Owens
2.1 Introduction 35
Section II Translational Biomarkers for Gene Therapy 61
3 Biomarker and Bioanalytical Readouts for the Development of AAV Gene Therapy 63
Yanmei Lu and Wibke Lembke
3.1 Introduction 63
3.2 Pharmacokinetic (PK) and Pharmacodynamic (PD) Biomarkers 66
3.3 Safety and Monitoring Biomarkers and Readouts 71
3.4 Predictive and Diagnostic Biomarkers for Study Enrollment and Patient Stratification 80
3.5 Summary 82
4 Nonclinical and Clinical Study Considerations for Biodistribution, Shedding, and Pharmacokinetics/Pharmacodynamics 87
Manuela Braun and Kefeng Sun
4.1 Biodistribution and Viral Shedding 87
4.2 Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling and Clinical Dose Selection of Gene Therapy 100
4.3 Summary 109
5 Immunogenicity of AAV Gene Therapy Products 117
Vibha Jawa and Bonnie Wu
5.1 Innate and Adaptive Immunity Induced by AAV-Based Gene Therapies 117
5.2 Preclinical Immunogenicity Risk Assessment 119
5.3 Clinical Manifestation Associated with Immunogenicity 123
5.4 Clinical Mitigation Strategy 127
Section III Bioanalysis for Gene Therapy 135
6 Bioanalytical Methods to Detect Preexisting and Post-administration Humoral Immune Responses Against AAV Capsid Proteins 137
Christian Vettermann and Boris Gorovits
6.1 Introduction 137
6.2 Considerations for AAV Total Antibody Assays 138
6.3 Considerations for Cell-based Transduction Inhibition Assays 145
7 Bioanalytical Methods to Study Biodistribution and Shedding of AAV-Based Gene Therapy Vectors 163
Christian Vettermann and Russell Soon
7.1 Introduction 163
7.2 Choice of Platform: qPCR vs. Digital PCR 164
7.3 Aspects of Method Development 168
7.4 Back-Calculation Formulas and Extraction Efficiency Assessments 172
7.5 Sensitivity Requirements 177
7.6 Specificity Requirements 179
7.7 Standard Curve Performance, Colinearity, Precision, and Accuracy 180
7.8 Selectivity Assessment and Matrix Interference 181
7.9 Sample Stability Considerations 182
7.10 Data Reporting Formats, Acceptance Criteria, and Trending 184
7.11 Immunocapture qPCR: An Ultra-Sensitive Method to Detect Intact AAV Capsids 187
8 Transgene mRNA Expression Analysis 193
Venkata Vepachedu and Hsing-Yin Liu
8.1 Purpose of Measuring Transgene mRNA 193
8.2 Technologies to Quantify Transgene Expression in Tissues 196
8.3 Summary 211
9 Quantification of Transgene Protein Expression and Biochemical Function 215
Robert Dodge and Liching Cao
9.1 Introduction 215
9.2 Transgene Protein Concentration Determination 216
9.3 Transgene Protein Activity Determination 224
9.4 Summary 234
10 Substrate and Distal Pharmacodynamic Biomarker Measurements for Gene Therapy 239
Liching Cao, Kai Wang, John Lin, and Venkata Vepachedu
10.1 Introduction 239
10.2 Technologies to Quantify Substrate and Distal PD Biomarker 241
10.3 Summary 265
11 Detection of Cellular Immunity to Viral Capsids and Transgene Proteins 271
Maurus de la Rosa and Magdalena Tary-Lehmann
11.1 Introduction 271
11.2 Methods for the Detection of Cellular Immune Responses 274
11.3 Validation of Cellular Assays Using PBMC (Example ELISPOT) 278
12 Detection of Humoral Response to Transgene Protein and Gene Editing Reagents 291
George Buchlis and Boris Gorovits
12.1 Pre- and Post-dose Humoral Immunity to Transgene-expressed Proteins 291
12.2 Relevance of Analytical Protocols Applied in Determining Immune Response to Protein Therapeutics to the Detection of Anti-Transgene Protein Responses 294
12.3 Analysis of Immune Response by Binding and Functional Antibody Assay Protocols 295
12.4 Comparative Analysis of the Immune Response Evaluation for Transgene Proteins that are Expressed Extracellularly vs. Intracellularly 297
12.5 Humoral Immune Response to Gene Editing Reagents 298
13 rAAV Integration: Detection and Risk Assessment 317
Jing Yuan, Irene Gil-Farina, Raffaele Fronza, and Laurence O. Whiteley
13.1 Introduction 317
13.2 Review of Regulatory Guidance and Discussion Points that Are Raised on AAV Carcinogenesis 324
13.3 Assessing the Biologic Relevance of AAV Integration Profile 335
13.4 Conclusion and Future Direction 337
14 Detection and Quantification of Genome Editing Events in Preclinical and Clinical Studies 347
Marina Falaleeva, Shengdar Tsai, Kathleen Meyer, and Yanmei Lu
14.1 Introduction 347
14.2 Regulatory Guidance on Engineered Nuclease On- and Off-target Assessment 352
14.3 Strategies and Methodologies to Evaluate On-target and Off-target Activities 353
14.4 Concluding Remarks 376
Section IV Companion Diagnostic Development for Gene Therapy 383
15 Introduction to Companion Diagnostics for Gene Therapy 385
Paul Bartel and Jennifer Granger
15.1 Introduction to Companion Diagnostics 385
15.2 Role in Gene Therapy 386
15.3 Overall Strategy 387
15.4 Development Process 387
15.5 Considerations for Commercialization 390
15.6 Conclusion 391
16 Validation for Gene Therapy Companion Diagnostics 393
Karen L. Richards and Kennon Daniels
16.1 Introduction 393
16.2 Development of CTAs for Use in GTx Clinical Trials 397
16.3 Best Practices for Sample Banking and Consent of Subjects 401
16.4 Design Considerations 402
16.5 Bridging Studies 404
16.6 Commensurate Regulatory Review and Approval of GTx cdx 406
16.7 Concluding Sections 406
17 Regulatory Considerations for Gene Therapy Companion Diagnostics 409
Mica Elizalde and Paul Bartel
17.1 Introduction 409
17.2 US Fda 409
17.3 European Union 416
17.4 Other Regulated Markets 420
17.5 Development Strategy with the Therapeutic 422
17.6 Partner Relationship 424
17.7 Commercial and Post-Approval Considerations 425
17.8 Final Word 426
Section V Regulatory Perspectives on Gene Therapy 429
18 Current Regulatory Landscape for Gene Therapy Product Development and the Role of Biomarkers 431
Laura I. Salazar-Fontana PhD and Mike Havert PhD
18.1 Introduction 431
18.2 What is Gene Therapy? 432
18.3 Biomarkers Defined 433
18.4 Early Gene Therapy Biomarkers 434
18.5 Current Expectations for Gene Therapy Biomarkers 437
18.6 Safety Biomarkers for Gene Therapy Products 438
18.7 Concluding Remarks 442
References 443
Index 449
Boris Gorovits, PhD is currently the Principal at Gorovits BioSolutions, LLC and previously worked at Sana Biotherapeutics, Pfizer and Wyeth Research. Dr. Gorovits has published 80+ journal articles and book chapters.
